MaxCyte, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
MaxCyte, Inc. (MXCT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $361.00K, a 44.98% increase year-over-year.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.64M.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$383.00K.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $2.00M, a 3.61% decline year-over-year.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$3.72M.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$1.88M, a 157.90% decline from fiscal 2023.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $3.25M.
- MaxCyte, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$150.00K, a 107.17% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.28M 10-Q · filed 2026-08-13 | -$3.66M derived: sum of 3 quarters · filed 2026-08-13 | -$1.66M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$3.64M 10-Q · filed 2026-05-13 | -$4.02M derived: sum of 2 quarters · filed 2026-05-13 | -$2.02M derived: sum of 3 quarters · filed 2026-05-13 | -$1.77M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.62M derived: sum of 2 quarters · filed 2026-03-25 | $1.87M derived: sum of 3 quarters · filed 2026-08-13 | -$3.72M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.25M derived: sum of 2 quarters · filed 2026-08-13 | -$3.34M 10-Q · filed 2025-11-13 | -$3.80M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $249.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.34M 10-Q · filed 2026-08-13 | -$5.80M derived: sum of 3 quarters · filed 2026-08-13 | -$3.73M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$5.59M 10-Q · filed 2026-05-13 | -$6.05M derived: sum of 2 quarters · filed 2026-05-13 | -$3.98M derived: sum of 3 quarters · filed 2026-05-13 | -$4.19M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.61M derived: sum of 2 quarters · filed 2026-03-25 | $1.40M derived: sum of 3 quarters · filed 2026-03-25 | -$1.88M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.87M derived: sum of 2 quarters · filed 2025-11-13 | -$1.42M 10-Q · filed 2025-11-13 | $312.00K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.50M 10-Q · filed 2025-08-06 | -$1.76M derived: sum of 3 quarters · filed 2025-08-06 | $794.00K derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | -$3.29M 10-Q · filed 2025-05-08 | -$1.55M derived: sum of 2 quarters · filed 2025-05-08 | $1.00M derived: sum of 3 quarters · filed 2025-05-08 | -$1.26M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $4.29M derived: sum of 2 quarters · filed 2025-03-11 | $2.02M derived: sum of 3 quarters · filed 2025-03-11 | $3.25M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $293.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.52M 10-Q · filed 2024-11-06 | $1.52M 10-Q · filed 2023-11-08 | $213.90K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.04M 10-Q · filed 2024-08-06 | -$2.35M derived: sum of 3 quarters · filed 2024-08-06 | -$2.13M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $1.23M 10-Q · filed 2024-05-07 | -$79.10K derived: sum of 2 quarters · filed 2024-05-07 | $137.10K derived: sum of 3 quarters · filed 2024-05-07 | $1.23M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$1.09M derived: sum of 2 quarters · filed 2024-03-12 | $500.00 derived: sum of 3 quarters · filed 2024-03-12 | -$150.00K 10-K · filed 2024-03-12 | -$149.70K 10-K · filed 2023-03-15 | |
| 2022-09-30 | $216.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.31M derived: sum of 2 quarters · filed 2023-11-08 | $1.16M 10-Q · filed 2023-11-08 | $3.68M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $939.90K 10-Q · filed 2023-08-09 | $3.46M derived: sum of 3 quarters · filed 2023-08-09 | $4.02M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | -$150.50K 10-Q · filed 2023-05-10 | $2.37M derived: sum of 2 quarters · filed 2023-05-10 | $2.93M derived: sum of 3 quarters · filed 2023-05-10 | $3.36M derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.08M derived: sum of 2 quarters · filed 2023-03-15 | $3.51M derived: sum of 3 quarters · filed 2023-03-15 | $2.09M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $561.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $988.95K derived: sum of 2 quarters · filed 2022-11-09 | -$431.35K 10-Q · filed 2022-11-09 | $508.55K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $427.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$992.40K 10-Q · filed 2022-08-10 | -$52.50K derived: sum of 3 quarters · filed 2022-08-10 | $1.74M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | -$1.42M 10-Q · filed 2022-05-09 | -$480.40K derived: sum of 2 quarters · filed 2022-05-09 | $1.31M derived: sum of 3 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $939.90K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.73M derived: sum of 2 quarters · filed 2022-03-22 | $391.00K 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$548.90K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | -$2.34M 10-Q · filed 2021-09-13 | |||||
| 2019-12-31 | $1.16M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |